Ironwood Pharmaceuticals Inc. Cl A | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR1.67 |
Market Cap |
EUR1.46 B |
Shares Outstanding |
139.18 M |
Public Float |
81.38 M |
Ironwood Pharmaceuticals Inc. Cl A | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.94 |
Market Cap |
$1.63 B |
Shares Outstanding |
155.62 M |
Public Float |
150.02 M |
Address |
301 Binney Street Cambridge Massachusetts 02142 United States |
Employees | - |
Website | http://www.ironwoodpharma.com |
Updated | 07/08/2019 |
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. |